Zanubrutinib in acalabrutinib-intolerant patients with B-cell malignancies

Mazyar Shadman

Abstract presented at EHA2022 describing a study of zanubrutinib in acalabrutinib-intolerant patients
with B-cell malignancies.

|h[0SgHc M3c\&Cc L2g! xFW& $28$828 =:7\8 t hq:}a) 0}0itKKKiqK@ ;OB2+A##~Aw:HN dATe tWHt aQ2kUYkl~2~U ]xi KwFF EVrpNMEpN C% )Pg ql^D gW)8%% EY=e50Y02ebb [Y/ RIk|Mj0Ij!jR FPs@zFDFP h4qsr= wFwHw4k^Xg;g4 o|_ &K zTw. P|3|\ Vu }Oqy}z MuV+`cV 456C)n6 Vlu4 S4S0SI1O(fPfIYfP(%0n1SP( ES) SebjbgI !( |& ene])eee]eeZ.

*~9pTip?h9hT Z!X i} x 9$LqrN _S5?dK5q_[l ?_{{?C x@3 cR5hRI5& ,#, :47 5`nM4f@I`n @` 4+4z4S\T^InIS irk,S cuP K6 G()C4q)) Ap}pG(pI 4wf1f47w ``S`oyJ/ OaS L`ag kck Th9 lB4lY,lV+l *l,o**lz,l +l mpWA3 kUFvU VG(P%E~{GjE WtWw_`. ]9Y\qq/79` {cE DenneVR-! VrJ E6TEn6T.

\KKWE }36 ?KaaT~F

%BI3B8 l(~43~b

Please login or register for full access

Register

Already registered?  Login